Wockhardt epoetin
Epoetin alfa and zeta biosimilar developed by Wockhardt. Reference product Eprex (Epogen and Procrit in the United States).
About Wockhardt epoetin
Wockhardt received a new epoetin permission in India in February 2023. Wockhardt's original epoetin, Wepox, was launched in 2001 and predates the published lists, making it one of the first Indian biosimilars of any kind.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Wockhardt epoetin holds an approval, these are the other epoetin alfa and zeta biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 3 | Bioviz Technologies (Bioviz epoetin), Not stated in the CDSCO list (Cipla epoetin), Zydus Lifesciences (Zydus epoetin) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Wockhardt: Wockhardt insulin glargine, Wockhardt pegfilgrastim.
Chronology
- CDSCOFeb 2023CDSCO permission granted
Sources
Planning epoetin alfa and zeta biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant